Autogene Cevumeran + Atezolizumab for Cancer

No longer recruiting at 52 trial locations

Overseen By Reference Study ID Number: GO39733 https://forpatients.roche.com/

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Genentech, Inc.

Must not be taking: MAOIs, Immunosuppressives

Disqualifiers: Liver disease, CNS metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to test the safety and effectiveness of two treatments: autogene cevumeran (an experimental treatment) and atezolizumab (an immunotherapy drug), either alone or in combination, for certain types of cancer. The focus is on cancers that have not responded well to standard treatments, such as non-small cell lung cancer and melanoma. Participants should have advanced cancer that hasn't improved with existing treatments. This study will help researchers understand the treatments' mechanisms and the body's reactions. As a Phase 1 trial, participants will be among the first to receive these treatments, aiding researchers in understanding their effects in people.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that you should not have had any anti-cancer therapy within 3 weeks before starting the study, and you should not be on systemic immunosuppressive medications within 2 weeks prior to starting. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Studies have shown that autogene cevumeran is safe and well-tolerated in small groups of cancer patients. Research indicates that it can trigger a specific immune response against cancer. No serious safety issues have been reported so far.

For atezolizumab, much more information is available. It is an FDA-approved treatment for certain types of lung cancer. Reports suggest it has generally manageable side effects, and many people tolerate it well. Common side effects might include fatigue or cough, but these are usually not severe.

Overall, both treatments have a positive safety profile. Atezolizumab has been used for a long time, while autogene cevumeran remains under close study. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about Autogene Cevumeran combined with Atezolizumab because it offers a novel approach to treating cancers like non-small cell lung cancer (NSCLC) and melanoma. Unlike traditional treatments that often rely on chemotherapy or radiation, these drugs are part of an innovative immunotherapy strategy. Autogene Cevumeran is a personalized mRNA-based vaccine that prompts the immune system to target and attack cancer cells, while Atezolizumab is an immune checkpoint inhibitor that prevents cancer from evading immune detection. Together, they offer a promising approach by enhancing the body's natural defenses to fight cancer more effectively.

What evidence suggests that this trial's treatments could be effective for cancer?

Research has shown that atezolizumab can extend the lives of people with advanced non-small cell lung cancer (NSCLC) compared to other treatments. Early studies on autogene cevumeran suggest it can help the immune system fight cancer by targeting specific parts of the tumor. In this trial, participants will receive autogene cevumeran either alone or with atezolizumab. Initial trials demonstrated that autogene cevumeran can work against tumors when used alone or with atezolizumab. Combining autogene cevumeran with atezolizumab might enhance the body's ability to fight cancer by boosting the immune response. ^{6 7 8 9 10}

Who Is on the Research Team?

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Are You a Good Fit for This Trial?

This trial is for adults with certain advanced cancers (like melanoma, lung, bladder, colorectal) that have worsened after standard treatment or where such treatments aren't suitable. Participants should be relatively healthy otherwise (ECOG 0-1), have a life expectancy of at least 12 weeks, and not have had recent major surgeries or immune system issues.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity but can do light work.

My kidneys are functioning well, with a creatinine clearance rate of at least 50 mL/min.

I have advanced NSCLC and haven't been treated with specific immune therapies.

Exclusion Criteria

I have not received neoantigen-specific or whole-tumor cancer vaccines, except as allowed.

I do not have an active brain tumor or untreated brain metastases.

I have had my spleen removed.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose-Escalation Treatment

Participants receive autogene cevumeran at escalated dosages, with or without atezolizumab, to evaluate safety and pharmacokinetics

8-12 weeks

Dose Exploration and Expansion

Participants receive autogene cevumeran and atezolizumab at various dose levels to explore and expand treatment efficacy and safety

12-16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Atezolizumab
• Autogene Cevumeran

Trial Overview The study is testing Autogene Cevumeran alone and combined with Atezolizumab in patients with various advanced cancers. It's an early-phase trial to check the safety and how well these treatments work together while monitoring the body's immune response.

How Is the Trial Designed?

Group I: Phase Ib: Dose Exploration: Autogene Cevumeran + Atezolizumab Experimental Treatment 2 Interventions

Non-small cell lung cancer (NSCLC) or melanoma cancer immunotherapy (CIT)-treated participants will receive autogene cevumeran (at dosage lower than maximum tolerated dose \[MTD\] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.

Group II: Phase 1b Flat Dose Escalation: Autogene Cevumeran + Atezolizumab Experimental Treatment 2 Interventions

Participants will receive autogene cevumeran at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg)

Group III: Phase 1b Expansion: Autogene Cevumeran + Atezolizumab (Serial Biopsy) Experimental Treatment 2 Interventions

CIT-naive patients with selected tumor types who consent to optional serial biopsies will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a dixed dose of 1200 mg.

Group IV: Phase 1b Expansion: Autogene Cevumeran + Atezolizumab Experimental Treatment 2 Interventions

Participants with different indications as per inclusion criteria will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.

Group V: Phase 1a Flat Dose Escalation: Autogene Cevumeran Experimental Treatment 1 Intervention

Participants will receive autogene cevumeran at escalated dosages.

Atezolizumab is already approved in United States, European Union for the following indications:

Approved in United States as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

Approved in European Union as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

Who Is Running the Clinical Trial?

Genentech, Inc.

Lead Sponsor

Trials

1,578

Recruited

569,000+

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

BioNTech SE

Industry Sponsor

Trials

84

Recruited

120,000+

Prof. Dr. Ugur Sahin

BioNTech SE

Chief Executive Officer since 2008

MD from University of Cologne

Prof. Özlem Türeci

BioNTech SE

Chief Medical Officer since 2018

MD from Saarland University

Published Research Related to This Trial

Atezolizumab is an FDA-approved treatment for advanced bladder cancer that works by blocking the PD-L1/PD-1 immune checkpoint, enhancing T-cell immunity against tumors.

In clinical trials, atezolizumab showed a 15% objective response rate in patients whose cancer progressed after chemotherapy, and a 24% response rate in chemotherapy-naïve patients, with a favorable safety profile compared to other second-line treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Inman, BA., Longo, TA., Ramalingam, S., et al.[2022]

Atezolizumab significantly improved overall survival in patients with previously treated non-small-cell lung cancer compared to docetaxel, with median survival times of 13.8 months versus 9.6 months, respectively.

The safety profile of atezolizumab was favorable, with only 15% of patients experiencing grade 3 or 4 adverse events, compared to 43% in the docetaxel group, indicating it may be a safer treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al.[2022]

Atezolizumab significantly improves overall survival in patients with metastatic non-small cell lung cancer (mNSCLC), with median survival times of 13.8 months in the atezolizumab group compared to 9.6 months in the docetaxel group in the OAK trial.

The treatment has an acceptable safety profile, with common side effects including fatigue and decreased appetite, and serious immune-related adverse events occurring in a small percentage of patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. Weinstock, C., Khozin, S., Suzman, D., et al.[2022]

Atezolizumab, a monoclonal antibody targeting PD-L1, has shown significant improvements in progression-free and overall survival in patients with advanced non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) when combined with chemotherapy, as demonstrated in the IMpower studies.

The safety profile of atezolizumab in combination with chemotherapy is acceptable, with common immune-related adverse events including rash (18-28%), hypothyroidism (8-15%), and hepatitis (5-17%), consistent with its known effects as a single agent, indicating no new safety concerns.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Manzo, A., Carillio, G., Montanino, A., et al.[2022]

Atezolizumab, an immune checkpoint inhibitor, has been shown to significantly prolong overall survival in patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy, based on results from the phase II POPLAR and phase III OAK trials.

The treatment is particularly effective in patients with higher PD-L1 expression, demonstrating higher objective response rates, and it has a manageable safety profile with a low incidence of immune-related adverse events.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. Blair, HA.[2020]

Atezolizumab, an inhibitor of PD-L1, was found to be well tolerated in a phase 1-2 trial involving 90 children and young adults with refractory or relapsed solid tumors, with no fatal adverse events reported.

While only 5% of patients achieved an objective response, the study showed comparable serum concentrations of atezolizumab between children and young adults, suggesting potential for future research into optimizing immune checkpoint inhibitors for specific patient populations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Geoerger, B., Zwaan, CM., Marshall, LV., et al.[2020]

In the phase III IMagyn050 trial involving patients with newly diagnosed ovarian cancer, the addition of atezolizumab to standard chemotherapy did not improve progression-free survival (PFS) in patients with BRCA1/2 mutations or homologous recombination deficiency (HRD).

Despite the presence of BRCA1/2 mutations or HRD, most ovarian tumors exhibited low tumor mutation burden (TMB), indicating that genomic instability does not predict enhanced sensitivity to immune checkpoint inhibitors like atezolizumab.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Landen, CN., Molinero, L., Hamidi, H., et al.[2023]

Atezolizumab, a monoclonal antibody targeting PD-L1, showed a 23% response rate and a median overall survival of 15.9 months in 119 patients with metastatic urothelial cancer who were unfit for cisplatin, indicating its efficacy as a front-line treatment.

In patients whose tumors progressed after first-line chemotherapy, atezolizumab had a 15% response rate and a median overall survival of 7.9 months, with better outcomes (26% response rate) in those with high PD-L1 expression, demonstrating its potential effectiveness based on biomarker status.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]. Bernard-Tessier, A., Bonnet, C., Lavaud, P., et al.[2019]

Atezolizumab is a monoclonal antibody that targets PD-L1, which is being developed for treating various blood cancers and solid tumors, showing promise in cancer immunotherapy.

It has already been approved in the US as a second-line treatment for urothelial carcinoma and is pending approval for non-small cell lung cancer, highlighting its potential efficacy in these conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab: First Global Approval. Markham, A.[2019]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9716834/

updated long-term efficacy of atezolizumab in a diverse ... In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety.

2. tecentriq.com tecentriq.com/metastatic-nsclc/results/how-tecentriq-may-help.html

Effectiveness & Safety of TECENTRIQ® (atezolizumab) for ... TECENTRIQ helped people with a type of metastatic non-small cell lung cancer (NSCLC) live longer. TECENTRIQ was studied in 4 clinical trials with over 2000 ...

3. frontiersin.org frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.909027/full

Efficacy of Atezolizumab for Advanced Non-Small Cell ... OS was substantially improved by atezolizumab compared to chemotherapy-based treatment (HR 0.84; 95% CI, 0.76–0.92; p = 0.0002), according to ...

4. sciencedirect.com sciencedirect.com/science/article/pii/S0169500223009170

Results of the IFCT-1905 CLINATEZO real-world study Atezolizumab was continued beyond progression in 122 patients (23.6%) for a median duration of 1.9 months (95% CI: [1.4–2.3]). Best objective response was ...

5. jamanetwork.com jamanetwork.com/journals/jamanetworkopen/fullarticle/2786029

Comparative Effectiveness of Atezolizumab, Nivolumab ... This study found that atezolizumab was associated with superior OS compared with docetaxel and similar OS compared with nivolumab in a real-world cohort of ...

6. tecentriq.com tecentriq.com/safety.html

Important Safety Information | TECENTRIQ® (atezolizumab) What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

7. tecentriq-hcp.com tecentriq-hcp.com/metastatic-nsclc/side-effects/important-safety-information.html

Important Safety Information | TECENTRIQ® (atezolizumab) Find important safety information for TECENTRIQ® (atezolizumab), a treatment option for metastatic non-small cell lung cancer (NSCLC). See full safety for

8. tecentriq-hcp.com tecentriq-hcp.com/

TECENTRIQ® (atezolizumab) HCP | Efficacy, Safety, PI & MOA Information for healthcare professionals about the safety, efficacy, dosing, prescribing information and mechanism of action for TECENTRIQ® (atezolizumab).

9. tecentriq.com tecentriq.com/metastatic-nsclc/side-effects/important-safety-information.html

Indication and Important Safety Information Learn about the safety of TECENTRIQ® (atezolizumab) for metastatic non-small cell lung cancer (mNSCLC).

10. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7978274/

a global single-arm safety study of atezolizumab monotherapy ... Atezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer.